← Leaderboards
Mariusz W Szkudlinski
Trophogen, Inc.
$3,875,586
Attributed
$7,643,171
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,493,171 · 6
FDA$150,000 · 1
By mechanism
R44$7,246,291 · 4
R43$396,880 · 3
Top collaborators
- Bruce Dale Weintraub14 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogBioreactorsRecombinantsChinese Hamster Ovary CellRoller BottleAnimalsIn VitroGenerationsIn VivoLegal PatentSmall Business Innovation Research GrantSalesAffectWomanCommercializationDiagnosisSerumMalignant Neoplasm Of ThyroidFutureGlycoproteinsHormonesHuman Follicle Stimulating HormoneInjectionsRodent
Grant awards (15)
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$345,085
R44 · FY2021 · CA
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle$727,601
R44 · FY2020 · HD
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$433,685
R44 · FY2020 · CA
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$942,701
R44 · FY2019 · HD
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$778,770
R44 · FY2019 · CA
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle$733,166
R44 · FY2019 · HD
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$825,420
R44 · FY2018 · HD
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$285,070
R44 · FY2018 · CA
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$299,999
R44 · FY2017 · HD
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle$138,880
R43 · FY2017 · HD
Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer$765,782
R44 · FY2015 · CA
Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer$825,054
R44 · FY2014 · CA
Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer$283,958
R44 · FY2013 · CA
Novel High Affinity and Long-Acting Bovine FSH Analogs for Veterinary Superovulat$150,000
R43 · FY2012 · FD
Development of Novel VEGF Analogs$108,000
R43 · FY2005 · DK